Â鶹ѧÉú¾«Æ·°æ

Christopher Nevala-Plagemann
Rating: 4.9 of 5
( out of 176 reviews )

Christopher Nevala-Plagemann, MD, MSCI

Languages spoken: English

Clinical Locations

Primary Location

Huntsman Cancer Institute - Cancer Hospital South

Clinic 3A, Gastrointestinal
1950 Circle of Hope
Salt Lake City , UT 84112
801-646-4365

Sugar House Health Center

1280 E. Stringham Avenue
Salt Lake City , UT 84106
801-581-2000

  • Dr. Chris Nevala-Plagemann is a board-certified medical oncologist and Assistant Professor of Oncology at the Huntsman Cancer Institute. His clinical practice is dedicated to the care of patients with gastrointestinal malignancies, with a focus on integrating cutting-edge science into compassionate, patient-centered care.

    Dr. Nevala-Plagemann serves as principal or sub-investigator on numerous cooperative group, industry sponsored, and investigator-initiated clinical trials with experience across all trial phases. His recent trials include studies of KRAS-targeted therapies, novel immunotherapy combinations, and innovative supportive-care interventions focused on minimizing the toxicity of currently available therapies.

    Beyond clinical trial research, Dr. Nevala-Plagemann's academic interest centers on utilizing real-world datasets to optimize treatment strategies and outcomes. Through collaborations with his colleagues in labs at the University of Utah he is also working to better understand how the human microbiome impacts cancer development, progression, and response to therapy. This overarching goal is to accelerate the translation of new discoveries into therapies that meaningfully improve his patients' lives.

    Dr. Nevala-Plagemann received his medical degree from the University of Minnesota, where he conducted gene-editing research at the University of Minnesota Stem Cell Institute using early versions of the CRISPR/Cas9 system. He completed his residency in Internal Medicine, fellowship in Medical Oncology, and a Master of Science in Clinical Investigation at the University of Utah.

    At the Huntsman Cancer Institute, Dr. Nevala-Plagemann directs the Undiagnosed Tumor Clinic and serves as core faculty for the University of Utah Hematology/Oncology Fellowship Program. He has been recognized as a Best Oncologist in Utah (Salt Lake City Weekly Magazine, 2024) and is an active member of national and international organizations including SWOG Cancer Research Network, Alliance for Clinical Trials in Oncology, European Society for Medical Oncology, International Society for Diseases of the Esophagus, and the American Society of Clinical Oncology.

    Specialties

    Board Certification

    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Patient Rating

    Rating: 4.9 out of 5
    4.9 /5
    ( out of 176 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    September 18, 2025
    SUGAR HOUSE HEALTH CENTER
    Rating: 5 out of 5

    Dr Chris is simply the best. Excellence.

    September 17, 2025
    SUGAR HOUSE HEALTH CENTER
    Rating: 5 out of 5

    Dr. Nevala is a wonderful healthcare professional. His demeanor is calming, he explains processes and procedures well, and answers questions plainly. I hope that my interactions with him in the future are minimal, as he has guided me thru a very difficult battle. I do not hesitate to recommend him to anyone. He is a top notch professional.

    September 11, 2025
    SUGAR HOUSE HEALTH CENTER
    Rating: 5 out of 5

    Very satisfied with the care I received from Dr. Nevala-Plagemann.

    September 09, 2025
    SUGAR HOUSE HEALTH CENTER
    Rating: 5 out of 5

    Dr. Nevala is very knowledgeable, understanding and friendly.

    September 05, 2025
    SUGAR HOUSE HEALTH CENTER
    Rating: 5 out of 5

    He understands the chose we have to make without sugar coating the truth

    August 21, 2025
    SUGAR HOUSE HEALTH CENTER
    Rating: 5 out of 5

    He's wonderful!

    August 20, 2025
    SUGAR HOUSE HEALTH CENTER
    Rating: 5 out of 5

    He treated me very well

    August 13, 2025
    SUGAR HOUSE HEALTH CENTER
    Rating: 5 out of 5

    Both Doctors involved in virtual appointment were Very informative, direct, and compassionate

    August 06, 2025
    SUGAR HOUSE HEALTH CENTER
    Rating: 5 out of 5

    Great doctor

    See More Patient Comments

  • Dr. Chris Nevala-Plagemann is a board-certified medical oncologist and Assistant Professor of Oncology at the Huntsman Cancer Institute. His clinical practice is dedicated to the care of patients with gastrointestinal malignancies, with a focus on integrating cutting-edge science into compassionate, patient-centered care.

    Dr. Nevala-Plagemann serves as principal or sub-investigator on numerous cooperative group, industry sponsored, and investigator-initiated clinical trials with experience across all trial phases. His recent trials include studies of KRAS-targeted therapies, novel immunotherapy combinations, and innovative supportive-care interventions focused on minimizing the toxicity of currently available therapies.

    Beyond clinical trial research, Dr. Nevala-Plagemann's academic interest centers on utilizing real-world datasets to optimize treatment strategies and outcomes. Through collaborations with his colleagues in labs at the University of Utah he is also working to better understand how the human microbiome impacts cancer development, progression, and response to therapy. This overarching goal is to accelerate the translation of new discoveries into therapies that meaningfully improve his patients' lives.

    Dr. Nevala-Plagemann received his medical degree from the University of Minnesota, where he conducted gene-editing research at the University of Minnesota Stem Cell Institute using early versions of the CRISPR/Cas9 system. He completed his residency in Internal Medicine, fellowship in Medical Oncology, and a Master of Science in Clinical Investigation at the University of Utah.

    At the Huntsman Cancer Institute, Dr. Nevala-Plagemann directs the Undiagnosed Tumor Clinic and serves as core faculty for the University of Utah Hematology/Oncology Fellowship Program. He has been recognized as a Best Oncologist in Utah (Salt Lake City Weekly Magazine, 2024) and is an active member of national and international organizations including SWOG Cancer Research Network, Alliance for Clinical Trials in Oncology, European Society for Medical Oncology, International Society for Diseases of the Esophagus, and the American Society of Clinical Oncology.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Assistant Professor (Clinical)
    Academic Divisions Oncology
    Board Certification
    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Education history

    Graduate Training Clinical Investigation - University of Utah School of Medicine M.S.
    Fellowship Medical Oncology - University of Utah School of Medicine Fellow
    Residency Internal Medicine - University of Utah School of Medicine Resident
    Professional Medical Medicine - University of Minnesota Medical School M.D.
    Undergraduate Biology - Luther College B.A.

    Selected Publications

    Journal Article

    1. Miotke L, Norton C, Rubnitz Z, Florou V, Nevala-Plagemann C, Garrido-Laguna I (2025). Impact of DNA damage repair alterations on real-world response to therapy in metastatic colorectal cancer. ESMO Open, 10(9), 105768. ()
    2. Bhatti I, Rogers RE, Witt BL, Nevala-Plagemann C, Patterson-Fortin J (2025). A rare case report on esophageal squamous cell carcinoma metastatic to the pancreas. Front Oncol, 15, 1602987. ()
    3. Norton C, Shaw MS, Rubnitz Z, Smith J, Soares HP, Nevala-Plagemann CD, Garrido-Laguna I, Florou V (2025). KRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma. JAMA Network Open, 8(1), e2453588-e2453588.
    4. Norton C, Shaw MS, Rubnitz Z, Smith J, Soares HP, Nevala-Plagemann CD, Garrido-Laguna I, Florou V (2025). KRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma. JAMA Netw Open, 8(1), e2453588. ()
    5. Nevala-Plagemann C, Garrido-Laguna I (2024). NALIRIFOX for metastatic pancreatic adenocarcinoma: hope or hype? Nat Rev Clin Oncol, 21(8), 567-568. ()
    6. Florou V, Elliott A, Bailey MH, Stone D, Affolter K, Soares HP, Nevala-Plagemann C, Scaife C, Walker P, Korn WM, Lou E, Shroff RT, Hosein PJ, Garrido-Laguna I (2022). Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations in PACC. Clin Cancer Res, 29(17), 3408-3417. ()
    7. Nevala-Plagemann C, Sama S, Ying J, Shen J, Haaland B, Florou V, Garrido-Laguna I (2022). A Real-World Comparison of Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer in the United States. J Natl Compr Canc Netw, 21(3), 257-264. ()
    8. Miotke L, Nevala-Plagemann C, Ying J, Florou V, Haaland B, Garrido-Laguna I (2022). Treatment outcomes in recurrent versus de novo metastatic pancreatic adenocarcinoma: a real world study. BMC Cancer, 22(1), 1054. ()
    9. Nevala-Plagemann C, Iyengar S, Trunk AD, Pappas L, Haaland B, Garrido-Laguna I (2022). Treatment Trends and Clinical Outcomes of Left-Sided RAS/RAF Wild-Type Metastatic Colorectal Cancer in the United States. J Natl Compr Canc Netw, 20(3), 268-275. ()
    10. Trunk A, Braithwaite M, Nevala-Plagemann C, Pappas L, Haaland B, Garrido-Laguna I (2020). Real-World Outcomes of Patients With BRAF-Mutated Metastatic Colorectal Cancer Treated in the United States. J Natl Compr Canc Netw, 20(2), 144-150. ()
    11. Baron MK, Wang X, Nevala-Plagemann C, Moser JC, Haaland B, Garrido-Laguna I (2021). Survival Outcomes Based on Sequence of Therapy Using FOLFIRINOX and Nab-Paclitaxel + Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma. Pancreas, 50(6), 796-802. ()
    12. Florou V, Nevala-Plagemann C, Whisenant J, Maeda P, Gilcrease GW, Garrido-Laguna I (2021). Clinical Activity of Selitrectinib in a Patient With Mammary Analogue Secretory Carcinoma of the Parotid Gland With Secondary Resistance to Entrectinib. J Natl Compr Canc Netw, 19(5), 478-482. ()
    13. Nevala-Plagemann C, Moser J, Gilcrease GW, Garrido-Laguna I (2019). Survival of patients with metastatic HER2 positive gastro-oesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on front-line chemotherapy plus trastuzumab. ESMO Open, 4(4), e000539. ()
    14. Nevala-Plagemann C, Hidalgo M, Garrido-Laguna I (2019). From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. Nat Rev Clin Oncol.
    15. Nevala-Plagemann C, Francis S, Cavalieri C, Tao R, Whisenant J, Glasgow R, Scaife C, Lloyd S, Garrido-Laguna I (2018). Benefit of adjuvant chemotherapy based on lymph node involvement for oesophageal cancer following trimodality therapy. ESMO Open, 3(5), e000386. ()
    16. Nevala-Plagemann C, Lee C, Tolar J (2015). Placenta-based therapies for the treatment of epidermolysis bullosa. Cytotherapy, 17(6), 786-795. ()

    Review

    1. Rubnitz Z, Nevala-Plagemann C, Florou V, Garrido-Laguna I (2025). Gemcitabine-induced myositis in a patient with pancreatic cancer. [Review]. BMJ Case Rep, 18(1). ()
    2. Iyengar S, Nevala-Plagemann C, Garrido-Laguna I (2021). Updates on adjuvant and neoadjuvant treatment strategies for surgically resectable and borderline resectable pancreatic ductal adenocarcinoma. [Review]. Ther Adv Med Oncol, 13, 17588359211045861. ()
    3. Trunk A, Miotke L, Nevala-Plagemann C, Verdaguer H, Macarulla T, Garrido-Laguna I (2021). Emerging Treatment Strategies in Metastatic Pancreatic Cancer. [Review]. Pancreas, 50(6), 773-787. ()
    4. Nevala-Plagemann C, Hidalgo M, Garrido-Laguna I (2019). From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. [Review]. Nat Rev Clin Oncol, 17(2), 108-123. ()

    Case Report

    1. Rubnitz Z, Nevala-Plagemann CD, Florou V, Garrido-Laguna I (2025). Gemcitabine-induced myositis in a patient with pancreatic cancer. BMJ Case Rep, 18(1), e259660.
    2. Smith JT, Sama S, Florou V, Nevala-Plagemann C, Garrido-Laguna I (2023). Durable response to first-line PARP inhibition in BRCA-mutated metastatic cholangiocarcinoma: case report. J Gastrointest Oncol, 14(6), 2637-2643. ()
    3. Florou V, Nevala-Plagemann C, Barber KE, Mastroianni JN, Cavalieri CC, Garrido-Laguna I (2020). Treatment Rechallenge With Checkpoint Inhibition in Patients With Mismatch Repair-Deficient Pancreatic Cancer After Planned Treatment Interruption. JCO Precis Oncol, 4. ()
    4. Nevala-Plagemann C, Powers P, Mir-Kasimov M, Rose R (2019). A Fatal Case of Septic Shock Secondary to Acinetobacter Bacteremia Acquired from a Platelet Transfusion. Case Rep Med, 2019, 3136493. ()

    Editorial

    1. Nevala-Plagemann CD, Garrido-Laguna I (2024). NALIRIFOX for metastatic pancreatic adenocarcinoma: hope or hype? 21(8), 567-568.

    Letter

    1. Nevala-Plagemann C, Conroy T, Garrido-Laguna I (2024). Reply to 'NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3'. [Letter to the editor]. Nat Rev Clin Oncol, 21(12), 902. ()

    Abstract

    1. Nevala-Plagemann C, Pappas L, Haaland B, Garrido-Laguna I (2020). Treatment trends and clinical outcomes of left sided, RAS/RAF wild type metastatic colorectal cancer in the United States [Abstract]. 31(4), 438.

  • News & Podcasts

    Huntsman Cancer Institute News